Welcome to the investors section of Adocia
Adocia is a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins.
Latest Press Releases
2018/02/12Number of shares and voting rights of ADOCIA as of January 31, 2018
2018/02/12Adocia: additional resources allocated to the liquidity agreement
26-27 February 2018 Sachs, 11th Annual European Life Sciences CEO Forum & Exhibition, Zurich, Suisse - This global bio-pharma industry forum addresses the main challenges for 2018 in investment, partnering and alliance management. At this occasion, Olivier Soula, Adocia Deputy General Manager and R&D Director will attend this forum dedicated to innovation in the different therapeutic sectors.